Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib vs Trastuzumab in p95HER2+ Metastatic Breast Cancer
NCT01137994Phase 2Withdrawn
- Sponsor
- GSK
- Start
- Oct 2011
- Primary completion
- Dec 2016
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of lapatinib in breast cancer, sponsored by GSK. Planned start Oct 2011; status: withdrawn.
02
Drugs
lapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01137994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01137994.